SYMQY (SymBio Pharmaceuticals) Construction In Progress: $0.24 Mil (As of Dec. 2025)


SYMQY SymBio Pharmaceuticals Ltd SYMQY
36 GF Score
Price $0.56
GF Value $0.50
! 6 Warning Signs
View Full Analysis

What is SymBio Pharmaceuticals Construction In Progress?

SymBio Pharmaceuticals SYMQY -12.42% 36 Construction In Progress is $0.24 Mil as of Dec. 2025. GuruFocus rates SYMQY with a GF Score™ of 36/100 and a GF Value™ of $0.50. The stock has 6 warning signs investors should review.

SymBio Pharmaceuticals's quarterly construction in progress declined from Jun. 2025 ($0.26 Mil) to Sep. 2025 ($0.25 Mil) and declined from Sep. 2025 ($0.25 Mil) to Dec. 2025 ($0.24 Mil).

SymBio Pharmaceuticals's annual construction in progress declined from Dec. 2023 ($0.61 Mil) to Dec. 2024 ($0.29 Mil) and declined from Dec. 2024 ($0.29 Mil) to Dec. 2025 ($0.24 Mil).

SymBio Pharmaceuticals Construction In Progress Historical Data

* Premium members only.

The historical data trend for SymBio Pharmaceuticals's Construction In Progress can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

SymBio Pharmaceuticals Construction In Progress Chart

SymBio Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Construction In Progress
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.76 0.63 0.61 0.29 0.24

SymBio Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Construction In Progress Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.25 0.26 0.25 0.24 0.24
SYMQY
36GF Score
SymBio Pharmaceuticals Ltd SYMQY
Construction In Progress is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

SymBio Pharmaceuticals Construction In Progress Calculation

It records the cost of construction work, which is not yet completed (typically, applied to capital budget items). A construction in progress item is not depreciated until the asset is placed in service. Normally, upon completion, a construction in progress item is reclassified, and the reclassified asset is capitalized and depreciated.

What does a Construction In Progress of $0.24 Mil mean?
SymBio Pharmaceuticals (SYMQY) has a Construction In Progress of $0.24 Mil as of Dec. 2025. Construction in Progress records the amount of construction work that is not complete. View historical data on SymBio Pharmaceuticals and its competitors.
Is SymBio Pharmaceuticals' Construction In Progress too high?
SymBio Pharmaceuticals' current Construction In Progress is $0.24 Mil. Overall, SymBio Pharmaceuticals has a GF Score™ of 36/100, reflecting its overall financial health beyond just this single metric.
How does SymBio Pharmaceuticals' Construction In Progress compare to ZTS and UTHR?
SymBio Pharmaceuticals' Construction In Progress of $0.24 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Construction In Progress for a Drug Manufacturers company?
A good Construction In Progress depends on the Drug Manufacturers industry context. However, Construction In Progress should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Construction In Progress mean?
A high Construction In Progress can signal that a stock is expensive relative to its fundamentals. Construction in Progress records the amount of construction work that is not complete. View historical data on SymBio Pharmaceuticals and its competitors. SymBio Pharmaceuticals's current Construction In Progress is $0.24 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SymBio Pharmaceuticals stock overvalued right now?
SymBio Pharmaceuticals (SYMQY) has a current Construction In Progress of $0.24 Mil. The stock's GF Value™ is $0.50, compared to a current price of $0.56 — trading 11.6% above its estimated fair value. The current Construction In Progress is $0.24 Mil. SymBio Pharmaceuticals' overall GF Score™ is 36/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Construction In Progress calculated?
Construction In Progress is calculated from a company's financial statements. For SymBio Pharmaceuticals (SYMQY), the current Construction In Progress is $0.24 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is SymBio Pharmaceuticals (SYMQY) Overvalued in 2026?

Based on GuruFocus' analysis, SymBio Pharmaceuticals stock appears to be overvalued. The current stock price of $0.56 is trading 11.6% above its estimated GF Value™ of $0.50.

Key valuation signals for SYMQY:

  • Construction In Progress: $0.24 Mil
  • GF Value™: $0.50 vs. price of $0.56 (11.6% above fair value)
  • GF Score™: 36/100 with 6 warning signs

No single metric tells the full story. See the SYMQY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

SymBio Pharmaceuticals Business Description

Other Exchanges 4582:Japan
Address 1-28 Toranomon 4-chome, 7th Floor, Toranomon Towers Office, Minato-ku, Tokyo, JPN, 105-0001
SymBio Pharmaceuticals Ltd is a biopharmaceutical company engaged in development of new drugs with a primary focus on the treatment of rare diseases, mainly in the areas of oncology, hematology and multiple viral infections, and conduct integrated business activities that encompass search for new drug candidates, development, manufacturing, and sales.
36GF Score

Get the complete analysis for SYMQY

Construction In Progress is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.56
Price
$0.50
GF Value